Alnylam Pharmaceuticals
ALNY
282 hedge funds and large institutions have $11.7B invested in Alnylam Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 102 increasing their positions, 65 reducing their positions, and 29 closing their positions.
162% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 29
57% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 65
19% more funds holding
Funds holding: 236 → 282 (+46)
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
14% more call options, than puts
Call options by funds: $165M | Put options by funds: $144M
14% more capital invested
Capital invested by funds: $10.3B → $11.7B (+$1.42B)
1.69% less ownership
Funds ownership: 95.45% → 93.75% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$461M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 3 |
BlackRock
New York
|
+$126M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$96.9M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$64.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$266M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$114M |
| 3 |
D.E. Shaw & Co
New York
|
-$89.2M |
| 4 |
Goldman Sachs
New York
|
-$76.2M |
| 5 |
PA
Perceptive Advisors
New York
|
-$57.5M |
ALNY Hedge Fund Activity: Q4 2017 in Review
282 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2017, worth a combined $11.7B — up 14% from $10.3B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new ALNY positions and 29 closed out — a net gain of 47 holders — while 102 added to existing stakes and 65 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $461M. The largest seller was Wellington Management Group, cutting an estimated $266M.
- 282 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2017, up from 236 in Q3 2017.
- Funds reported $11.7B of Alnylam Pharmaceuticals stock for Q4 2017, up 14% quarter-over-quarter.
- 76 funds opened new Alnylam Pharmaceuticals positions in Q4 2017 and 29 closed out, a net change of +47 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2017 was T. Rowe Price Associates, an estimated $461M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2017 was Wellington Management Group, an estimated $266M sold.
Based on aggregated 13F filings for Q4 2017.